Diversity Panel Discusses Asian Experience in Cancer Research Hosted by Society for Immunotherapy of Cancer and Others
Share Article
The Society for Immunotherapy of Cancer (SITC), in collaboration with the Chinese American Hematologist and Oncologist Network (CAHON) and the Indo-American Cancer Association (IACA), is pleased to release an important diversity panel discussion of society leaders sharing their experience as Asians working in the cancer research field.
Barriers to Asians and Pacific Islanders in Science and Medicine Diversity Panel Logo
This diversity panel features a timely and intimate discussion of the interactions my fellow Asian colleagues have experienced in the laboratory and the clinic, stories that are unfortunately all too common,” said SITC President Patrick Hwu, MD.
Milwaukee, WI (PRWEB) May 27, 2021 The Society for Immunotherapy of Cancer (SITC) is pleased to announce the reinvigoration of the society’s unique program
CAR-T Therapy: Combating Cytokine Release Syndrome
Sponsored Content by ACROBiosystemsMay 21 2021
CAR-T cell therapy offers the hope of a cure to a number of cancer patients. Yet, in spite of the great effectiveness, more attention has been paid to the toxicity of the therapy known as cytokine release syndrome (CRS).
This article is aimed at summarizing the main points of assessment, grading and management of CRS in CAR-T Therapy and provide answers to the following questions:
How to identify the onset of CRS clinically?
What is CRS management?
How to use tocilizumab in CRS management？
Assessment, grading and management of CRS in CAR-T therapy
Antengene and Calithera Biosciences Enter into Worldwide Exclusive License Agreement to Develop and Commercialize CD73 Inhibitor CB-708 (ATG-037) prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Compugen Reports First Quarter 2021 Results
USA - English
Updated data from COM701 Phase 1 combination and monotherapy studies to be presented at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting
Milestone rich 2021 to include data readouts from ongoing COM701 triple combination study and COM902 monotherapy study in Q4 2021
Initiation of Phase 1b cohort expansion study of COM701 with Opdivo® in Q2 2021 and Phase 1 COM701 with COM902 dual combination study in 2H 2021 will expand systematic DNAM axis clinical evaluation
News provided by
Share this article
Share this article
HOLON, Israel, May 13, 2021 /PRNewswire/ Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today reported financial results for the first quarter ended March 31, 2021.